

# Principles and Structure of a Research Protocol

**The Union, Paris, France**  
**MSF, Brussels, Belgium**



International Union Against Tuberculosis and Lung Disease



# BASIC STRUCTURE

- **Background and rationale to study**
- **Aim and objectives (the research question)**
- **Methods (includes ethics submission)**
- **Budget and time lines**
- **Justification**



# **Background and Rationale**

- **Country / context in which study is to be done**
- **The problem and what is known about it**
- **Are there knowledge gaps?**
- **Will this study fill those knowledge gaps?**



# Aim and Objectives

- **Aim is broad**
- **Objectives are more specific**



# For example: (1)

## **AIM**

To document the management and outcome of new smear-positive Pulmonary TB patients who fail first line treatment in Malawi



# For example: (2)

**Specific Objectives** are to determine:-

1. The number of new smear-positive PTB patients who failed treatment
2. The management of patients who failed
3. Their treatment outcomes on Re-Rx regimen
4. The culture and drug sensitivity results of those who failed and in relation to treatment outcomes



# Methods

- **Study design** (descriptive, case-control, cohort)
- **Setting – general and study site**
- **Participants** (and study period)
- **Data variables to be collected:**
  - exposure and outcome variables
  - data collection instrument (when data collected)
  - data validation
- **Sources of data**
- **Analysis and statistics** (sample size, if needed)
- **Ethics approval**



# Recurrent Tuberculosis in Malawi





# BACKGROUND: NTP in Malawi (1)

- Model “DOTS” Programme
- Management by District TB officers
- Excellent Monitoring and Evaluation, using Registers and quarterly cohort reporting
  
- 27,000 cases of TB registered per annum
- HIV-prevalence in TB patients = 70%



# The problem and rationale (2)

Between 1987 to 1999:

- % Patients registered nationally with Relapse smear-positive PTB in Malawi declined from 6% to 3%
- No reported cases of recurrent smear-negative TB

**BUT**

- HIV-prevalence in TB patients increased from 30% to 70%
- Research literature from Africa (4 studies) showed that recurrent TB increases as HIV-prevalence increases



# Annual TB recurrence

**HIV+ve**

**HIV-ve**

Zaire

18%

6%

(Perriens et al 1991)

Kenya

17%

0.5%

(Hawken et al 1993)

Zambia

22%

6%

(Elliott et al 1995)

S.Africa


16%

6%

(Sonnenberg et al 2001)



# **% Patients registered nationally with relapse smear-positive PTB in Malawi**



# HIV and TB in Malawi

<u>Year</u>	<u>Site</u>	<u>No. TB</u>	<u>% HIV-positive</u>
<b>1986</b>	<b>Zomba</b>	<b>125</b>	<b>26</b>
<b>1993</b>	<b>Mzuzu</b>	<b>167</b>	<b>67</b>
<b>1994</b>	<b>Blantyre</b>	<b>665</b>	<b>75</b>
<b>1995</b>	<b>Zomba</b>	<b>793</b>	<b>77</b>
<b>2000</b>	<b>Malawi</b>	<b>512</b>	<b>77</b>



# **The research question:**

Is the Malawi NTP missing recurrent tuberculosis under routine programme settings?



# AIM of the Study

**To determine whether patients who have been registered as “New TB” been previously diagnosed and treated as relapse smear-positive Pulmonary TB and recurrent smear-negative TB?**



# METHODS





# Design

- This will be a cross-sectional study involving a structured interview of TB patients

*[other study designs include descriptive, cross-sectional, case-control, and cohort – either prospective or retrospective]*



# Setting and site visits

- General: Malawi is a small country in Africa with high HIV and TB burden. There is a country-wide DOTS Programme and all patients spend the first two months of TB treatment in hospital receiving initial phase therapy
- Site visits: **All** hospitals in the country that register and treat patients with TB will be visited. These include 3 central hospitals, 22 district hospitals and 18 mission hospitals
- Timing of the visits: These hospitals will be visited between January and June 1999 as part of the routine NTP supervision



# Participants (patients)

- **All** patients who are in hospital receiving treatment during the initial phase and who have been registered as “New TB” will be interviewed using a structured questionnaire
- Patients will be identified by going round the TB wards (all patients are admitted to TB wards) in a set fashion and this will include all patients in their beds

*Patients not in their beds at the time will not be interviewed: a record will be made of TB registration number, age, sex, and type of TB*

# Variables, data collection and validation

- Variables to be collected include: -TB registration no., age, sex, type of TB, **previous history of TB**
- Those with previous history of TB will be asked: when, what type of TB, was treatment completed
- Data to be collected into a structured questionnaire
- Validation of data on previous TB will be done using TB identity cards wherever possible



# Sources of data:

- All patients in their TB beds will be interviewed
- Patients who are out of the TB ward and cannot be traced will not be included  
*[however, their age, sex and type of TB will be listed and compared with those in bed to ensure the two groups are similar]*



# Analysis and statistics

- Data will be entered into EPI-INFO software
- $X^2$  test will be used to compare differences in proportions between groups (odds ratios with 95% confidence intervals)
- Differences at 5% level ( $p < 0.05$ ) to be regarded as significant



# Sample size

Not calculated because this is a national study involving all patients in hospital at the time of the visit



# Ethics approval

- Study to be approved by the TB programme management group
- Ethics approval to be obtained from the Malawi National Health Science Research Committee





# BUDGET

<b>Research Activity</b>	<b>Costing (USD\$)</b>
Two NTP operational research officers for hotel accommodation and daily per diems	450
Stationary	50
<b>TOTAL</b>	<b>500</b>

*Research piggy-backed onto routine supervision and therefore less costly*



# JUSTIFICATION

If hypothesis is correct, and previously treated patients are incorrectly registered as “new patients”, then:-

- Incorrect treatment is administered
- Incorrect data are reported to WHO
- We need to find out why and educate District TB Officers about proper management



# Results

Type of TB	Registered as “New”	Previous TB
<b>All types</b>	<b>1254</b>	<b>94 (8%)</b>
Sm+ve PTB	746	34 (5%)
Sm-ve PTB	282	40 (14%)
EPTB	226	20 (9%)



Only 9 out of 94 previous episodes  
were validated with the patient  
producing an Identity card

# Analysis

Compared to patients with smear-positive PTB, a previous episode of TB was significantly more common in :-

- patients with smear-negative PTB  
(OR 3.5, 95% CI 2.1 - 5.7,  $p < 0.001$ )
- patients with EPTB  
(OR 2.0, 95% CI 1.1 - 3.7,  $p < 0.05$ )



# Interpretation of Study

- Patients with relapse TB and recurrent TB were incorrectly registered under routine programme settings as “new patients”
- This mistake was more common in patients with smear-negative PTB and EPTB
- The reasons for these mistakes were not identified



# What next?

- Results and implications of incorrect recording discussed with NTP staff at the annual NTP seminar held 3 months later
- Central Unit prepared interim guidelines about diagnosis and management of recurrent TB
- Guidelines were incorporated into revised National TB Manual about one year later



# **A similar study was conducted from Jan-Jun 2000**

- Same aim: to determine whether patients registered with “new smear-negative PTB or new EPTB” were correctly diagnosed
- Same methodology as the study in 1999 except the focus was on smear-negative PTB and EPTB





# Operational Research Jan-Jun 2000

<u>Type of TB</u>	<u>Registered “New”</u>	<u>Previous TB</u>
sm-ve PTB	214	10 (5%)
EPTB	213	2 (1%)

*[ a big improvement on the previous year ]*



**How did this  
operational research  
impact on the Malawi  
National TB Control  
Programme?**



# Malawi TB case notifications

Year	Total TB	New TB	Recurrent TB
1998	22674	22069	605 (3%)
1999	24396	23728	668 (3%)
<b><i>Interventions to improve correct recording of TB cases</i></b>			
2000	24846	22789	2057 (8%)
2001	27672	25217	2455 (9%)
2002	26532	23724	2808 (11%)
2003	28234	24791	3443 (12%)

***Recurrent TB = relapse, failure, treatment after default, recurrent sm-ve TB***

